Akèy › Kansè tete negatif triple › Utah
Etid klinik pou Kansè tete negatif triple nan Utah
23 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan Utah.
Vil nan Utah
Tèks ofisyèl etid la (Anglè)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06270706A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Intermountain Health, Salt Lake City
Ap rekriteFaz 1
Laj 19 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06586957A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Intermountain Medical Center ( Site 0074), Murray
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Intermountain Medical Center ( Site 0113), Murray
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06393374A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- University of Utah, Huntsman Cancer Institute ( Site 0056), Salt Lake City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06841354A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07020117Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05633654A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06400472A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07029399Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 13, 2026 · NCT05985655Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- START Mountain Region, West Valley City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05579366A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT07318805A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 22, 2026 · NCT05208762A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT05377996Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Start Mountain Region /ID# 276270, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT05005403A Study of LY4175408 in Participants With Advanced Cancer
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 23, 2026 · NCT07046923A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- START Mountain Region, LLC, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07503808Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT07517198I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
- START Mountain Region, West Valley City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 23, 2026 · NCT07190469JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- University of Utah Huntsman Cancer Institute, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jan 9, 2026 · NCT05490472Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Huntsman Cancer Institute - University of Utah, Salt Lake City
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Oct 29, 2025 · NCT06249048Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.